Inhibiting a transcriptional kinase already explored in oncology can suppress the pathological cellular transition associated with cartilage breakdown in osteoarthritis (OA), according to preclinical findings published in Bone Research. The study, led by Scott J. Roberts at the Royal Veterinary College (RVC) in London, UK, provides in vivo evidence that cyclin-dependent kinase 8 (CDK8) inhibition can modulate processes involved in endochondral ossification and OA, reducing cartilage pathology in a spontaneous mouse model while affecting cartilage, bone, and inflammatory pathways.
OA affects hundreds of millions of people worldwide, yet no disease-modifying OA drug (DMOAD) has reached the market. As the paper's authors note, "despite OA being the commonest form of arthritis, there are no disease-modifying therapeutics and clinical development of single-target approaches, including IL-1β and ADAMTS5, has failed despite promising data from preclinical models." CDK8, a kinase subunit of the Mediator transcriptional complex, was elevated in chondrocytes from human OA cartilage (Mankin scores 5–10) compared with non-lesion tissue, and lentiviral overexpression of CDK8 in chondrocyte models recapitulated pro-degenerative transcriptional signatures — supporting a functional rather than merely correlative role.
The central mechanism involves CDK8's phosphorylation of STAT1 at serine-727 and its regulation of downstream Wnt, TGF-β, BMP, and NF-κB pathways, all of which govern chondrocyte differentiation state. In healthy articular cartilage, chondrocytes maintain a stable, non-hypertrophic phenotype; in OA, they aberrantly transition toward hypertrophy — upregulating mineralization markers and degradative enzymes while losing matrix-producing capacity. CDK8 inhibition, the authors propose, acts as a transcriptional rheostat that stabilizes the non-hypertrophic state by suppressing this axis.
The in vivo component used male STR/Ort mice, a spontaneous OA model, dosed orally with 5 mg/kg of the selective CDK8/19 inhibitor MSC2530818 (MSC-818; biochemical IC₅₀ = 2.5 nmol/L) three times per week for 12 weeks, beginning at 22 weeks of age. Treated animals (n = 12 limbs from 6 mice) showed reduced Osteoarthritis Research Society International (OARSI) histological scores compared with vehicle-treated controls (n = 10 limbs from 5 mice), indicating attenuated cartilage degradation. Complementary matrix integrity scoring and Masson's Trichrome staining supported preservation of collagen architecture. Micro-computed tomography analysis showed reduced growth plate bridge number and areal density, particularly in the lateral compartment. Treadmill-based gait analysis indicated functional differences in treated animals consistent with reduced joint pathology. No overt toxicity was observed over the 12-week dosing period, though the study was not designed for formal safety profiling.
In vitro, the chondroprotective effects were validated across multiple structurally distinct CDK8 inhibitor series, reducing the likelihood that findings reflect off-target compound activity. Bulk RNA sequencing identified downregulation of NF-κB and JAK-STAT inflammatory pathways and upregulation of extracellular matrix organization programs. Seahorse metabolic profiling indicated that CDK8 inhibition shifted chondrocytes away from glycolysis-dominant metabolism toward preserved oxidative phosphorylation capacity — a metabolic profile associated with healthier chondrocyte function. Effects were directionally consistent across primary equine articular chondrocytes from six donors and in THP-1-derived macrophages, where CDK8 inhibition reduced phospho-STAT1 and pro-inflammatory cytokine expression.